ARROWHEAD PHARMACEUTICALS, INC. - FORM 10-Q - EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 - May 12, 2011

Attached files

file filename
10-Q - FORM 10-Q - ARROWHEAD PHARMACEUTICALS, INC.d10q.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 - ARROWHEAD PHARMACEUTICALS, INC.dex321.htm
EX-10.2 - STOCK PURCHASE AGREEMENT - ABLARIS THERAPEUTICS, INC. - ARROWHEAD PHARMACEUTICALS, INC.dex102.htm
EX-10.1 - STOCK PURCHASE AGREEMENT - CALANDO PHARMACEUTICALS, INC. - ARROWHEAD PHARMACEUTICALS, INC.dex101.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - ARROWHEAD PHARMACEUTICALS, INC.dex311.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - ARROWHEAD PHARMACEUTICALS, INC.dex312.htm

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b)

OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350

I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Research Corporation (the “Company”), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2011, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of the Company.

Date: May 12, 2011

 

/s/ Kenneth A. Myszkowski

Kenneth A. Myszkowski
Chief Financial Officer

A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Research Corporation and will be retained by Arrowhead Research Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

Stock widget

Investing forum

ARROWHEAD PHARMACEUTICALS, INC. Reports